Tvardi Therapeutics, Inc. (TVRD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TVRD currently has 9.38M outstanding shares. with significant dilution risk as 54.2M authorized shares could dilute existing holders by 578.2%. The company has significantly diluted shareholders by 1625.1% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 3 stock splits (positive for accessibility) and 3 reverse splits (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
POS AM filing: Resale by selling stockholders of up to 593,758 shares of common stock. |
9.4M | 54M |
| May 08, 2026 |
10-Q filing | 9.4M shares outstanding |
9.4M | 56M |
| May 01, 2026 |
S-3 filing: Tvardi Therapeutics, Inc. may offer and sell up to $200,000,000 of any combination of shares of its common stock, shares of its preferred stock, debt securities and warrants. |
9.4M | 56M |
| Mar 31, 2026 |
10-K filing | 9.4M shares outstanding |
9.4M | 0 |
| Nov 13, 2025 |
10-Q filing | 9.4M shares outstanding |
9.4M | 0 |
| Oct 20, 2025 |
S-1/A filing: This prospectus relates to the resale by certain of the selling stockholders named in this prospectus of up to 2,084,117 shares of our common stock issued to the selling stockholders pursuant to the Merger Agreement. |
8.5M | 0 |
| Oct 07, 2025 |
S-1/A filing: This prospectus relates to the resale by certain selling stockholders of up to 2,084,117 shares of our common stock. |
8.5M | 0 |
| Aug 14, 2025 |
10-Q filing | 8.5M shares outstanding |
8.5M | 0 |
| May 30, 2025 |
S-1 filing: This S-1 filing relates to the resale of up to 2,084,117 shares of common stock by selling stockholders, with the company not receiving any proceeds from the sale. |
9.4M | 0 |
| May 13, 2025 |
10-Q filing | 1.5M shares outstanding |
1.5M | 0 |
| Apr 15, 2025 |
Stock Split
8-K filing: Stock split 1-for-3 | Outstanding: 4,562,738 → 1,500,000 |
1.5M | 0 |
| Mar 11, 2025 |
10-K filing | 4.6M shares outstanding |
4.6M | 0 |
| Dec 31, 2024 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 4,568,491 → 380,707 |
380K | 20K |
| Dec 30, 2024 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 54,843,841 → 4,568,491 |
4.6M | 240K |
| Nov 14, 2024 |
10-Q filing | 54.8M shares outstanding |
55M | 2.9M |
| Aug 14, 2024 |
10-Q filing | 54.7M shares outstanding |
55M | 3M |
| May 13, 2024 |
10-Q filing | 54.6M shares outstanding |
55M | 3.2M |
| Mar 06, 2024 |
10-K filing | 54.1M shares outstanding |
54M | 3.6M |
| Nov 13, 2023 |
10-Q filing | 54.2M shares outstanding |
54M | 3.5M |
| Aug 07, 2023 |
10-Q filing | 54.0M shares outstanding |
54M | 3.8M |
| May 15, 2023 |
10-Q filing | 53.9M shares outstanding |
54M | 3.9M |
| Mar 06, 2023 |
10-K filing | 53.7M shares outstanding |
54M | 4.1M |
| Nov 07, 2022 |
10-Q filing | 53.7M shares outstanding |
54M | 4M |
| Aug 08, 2022 |
10-Q filing | 53.6M shares outstanding |
54M | 4.1M |
| May 09, 2022 |
10-Q filing | 53.5M shares outstanding |
54M | 4.3M |
| Mar 01, 2022 |
10-K filing | 50.7M shares outstanding |
51M | 7M |
| Mar 01, 2022 |
S-3 filing: The filing is for a shelf registration to offer up to $300,000,000 of any combination of Common Stock, Preferred Stock, Debt Securities and Warrants, and also details an at-the-market offering for up to $80,000,000 of common stock through Jefferies. |
53M | 4.3M |
| Nov 08, 2021 |
10-Q filing | 50.1M shares outstanding |
50M | 0 |
| Aug 31, 2021 |
8-K filing: Cara Therapeutics will receive a $50.0 million investment from Vifor Pharma in Cara's common stock at a price of $15.23 per share, equaling 3,282,391 shares, contingent on Hart-Scott-Rodino Act waiting period. ($50.0M proceeds) |
50M | 0 |
| Aug 09, 2021 |
10-Q filing | 50.1M shares outstanding |
50M | 0 |
| May 10, 2021 |
10-Q filing | 49.9M shares outstanding |
50M | 0 |
| Feb 25, 2021 |
10-K filing | 47.9M shares outstanding |
48M | 0 |
| Nov 09, 2020 |
10-Q filing | 46.9M shares outstanding |
47M | 0 |
| Oct 20, 2020 |
8-K filing: Cara Therapeutics, Inc. entered into a license agreement with Vifor Pharma, including a $50 million investment in Cara's common stock at $17.0094 per share. ($50.0M proceeds) |
47M | 0 |
| Aug 10, 2020 |
10-Q filing | 46.8M shares outstanding |
47M | 0 |
| May 11, 2020 |
10-Q filing | 46.7M shares outstanding |
47M | 0 |
| Feb 27, 2020 |
10-K filing | 46.7M shares outstanding |
47M | 0 |